Despite a recent share price hike, Mersana Therapeutics' P/S...
Despite a recent share price hike, Mersana Therapeutics' P/S ratio lags behind others due to forecasted revenue decline. Without major changes, a drastic stock price rise is unlikely.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000317f8e75591d45.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment